The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
Open accessAbstract
OBJECTIVE: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). METHODS: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new gadolinium-enhancing lesions (per brain MRI) at week 12. Relapses and safety/tolerability were assessed, and CD19+ peripheral blood B-lymphocyte counts measured. Safety monitoring continued weeks 24 to 48 with subsequent individualized follow-up evaluating B-cell repletion. RESULTS: < 0.001). Post hoc analysis (excluding weeks 1-4) estimated a ≥90% lesion reduction vs placebo (week 12) for all cumulative ofatumumab doses ≥30 mg/12 wk. Dose-dependent CD19 B-cell depletion was observed. Notably, complete depletion was not necessary for a robust treatment effect. The most common adverse event was injection-related reactions (52% ofatumumab, 15% placebo), mild to moderate severity in 97%, most commonly associated with the first dose and diminishing on subsequent dosing. CONCLUSION: Imaging showed that all subcutaneous ofatumumab doses demonstrated efficacy (most robust: cumulative doses ≥30 mg/12 wk), with a safety profile consistent with existing ofatumumab data. This treatment effect also occurred with dosage regimens that only partially depleted circulating B cells. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationTeeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cited by
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 734
Self-citationB cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Self-citationRole of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Self-citationB cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Self-citation
Metadata
- Authors
- Bar-Or, A., Grove, R. A., Austin, D. J., Tolson, J. M., VanMeter, S. A., Lewis, E. W., Derosier, F. J., Lopez, M. C., Kavanagh, S. T., Miller, A. E., & Sorensen, P. S.
- Venue
- Neurology
- Published
- 2018-05-15
- Volume
- 90
- Issue
- 20
- Pages
- e1805-e1814
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2802139618
- Cited by
- 219
- References
- 3
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. https://app.cochat.ai/papers/10.1212/wnl.0000000000005516
- The paper
- Bar-Or, A., Grove, R. A., Austin, D. J., Tolson, J. M., VanMeter, S. A., Lewis, E. W., Derosier, F. J., Lopez, M. C., Kavanagh, S. T., Miller, A. E., & Sorensen, P. S. (2018). Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. https://doi.org/10.1212/wnl.0000000000005516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.